A progesterone-induced protein increases the synthesis of asymmetric antibodies.
The immunological effects of progesterone are mediated by a 34-kDa protein named the progesterone-induced blocking factor (PIBF). PIBF induces increased production of Th2-type cytokines; thus, it might stimulate antibody synthesis by B cells. There is a population of antibodies which, owing to the presence of a mannose-rich oligosaccharide residue on one of the Fab arms of the molecule, possess an asymmetric structure. Due to the asymmetric structure these molecules have no effector functions; however, they might act as blocking antibodies. This study was aimed at investigating the effect of progesterone-dependent immunomodulation on antibody production by B cells, with special emphasis on the synthesis of asymmetric nonprecipitating antibodies. The ratio of asymmetric IgG was significantly higher in supernatants of hybridoma cells cultured in the presence of PIBF than in those cultured in the absence of PIBF. Lymphocytes from healthy pregnant women produce significantly more PIBF than those of women with pathological pregnancies. The present studies revealed a positive relationship between asymmetric antibody content of the sera and PIBF expression on lymphocytes. Blocking of progesterone receptors by RU 486 or neutralizing endogenous PIBF activity by specific antibody significantly reduced the production of asymmetric antibodies in pregnant mice. Effector function of conventional and asymmetric antibodies was compared in a TNF alpha neutralization assay. Purified asymmetric anti-TNF alpha antibodies did not neutralize the cytotoxic effect of TNF alpha on L929 murine fibroblast target cells, whereas conventional anti-TNF alpha antibodies in the same concentration significantly (P < 0.001) reduced cytotoxicity. Our data suggest that PIBF induces increased production of asymmetric antibodies. These antibodies fail to exhibit effector functions and by blocking fetally derived antigens might contribute to protection of the fetus.
Department of Microbiology, University Medical School of Pecs, Hungary.
K
K
Kelemen
I
I
Bognar
M
M
Paal
J
J
Szekeres-Bartho
D000818:Animals; D019138:Antibodies, Blocking / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D015735:Mifepristone / Q000494:pharmacology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000502:physiology*; D011374:Progesterone / Q000494:pharmacology*; D013491:Suppressor Factors, Immunologic; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D019138:Antibodies, Blocking; C110058:PIBF1 protein, human; C491677:Pibf1 protein, mouse; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; D014409:Tumor Necrosis Factor-alpha; D015735:Mifepristone; D011374:Progesterone